InfuSystem Holdings, Inc INFU
Medical/Dental Instruments · data as of November 13, 2026
InfuSystem Holdings, Inc (INFU) is a healthcare company listed in the US with a market value of about $295M. In the twelve months to September 30, 2026 it had revenue of $144M and net income of $9M, a net margin of 6.5%.
Its overall Stock Analiz score is 2.6 out of 5 (average). The strongest part is financial health (5/5); the weakest is value (1/5).
Key numbers: a P/E of 33.5, a price to free cash flow of 11.9, 5-year revenue growth of 8% a year, a 5-year average ROIC of 5%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 42% below the current price.
About InfuSystem
InfuSystem is listed in the US and classified in medical/dental instruments. Revenue went from $71M in 2015 to $143M in 2025, growth of about 7.4% a year. It was profitable in 7 of the last 10 years in our data. Its share count fell by 2% over three years (buybacks).
Score: 2.6 / 5
Checks passed
- P/FCF below 20
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $144M | $143M | $135M | $126M | $110M | $102M | $97M | $81M | $67M | $71M | $70M |
| Net income | $9M | $7M | $2M | $872000 | $18000 | $1M | $17M | $1M | -$1M | -$21M | -$222000 |
| Free cash flow | $25M | $24M | $19M | $10M | $17M | $17M | $19M | $11M | $11M | $8M | $8M |
| EPS (diluted) | $0.44 | $0.31 | $0.11 | $0.04 | $0.00 | $0.06 | $0.80 | $0.07 | $-0.05 | $-0.91 | $-0.01 |
| Net margin | 6.5% | 4.6% | 1.7% | 0.7% | 0.0% | 1.4% | 17.8% | 1.7% | -1.6% | -29.1% | -0.3% |
| ROIC | — | 9.1% | 6.2% | 3.6% | 1.5% | 2.6% | 8.3% | 4.7% | 0.6% | -5.1% | 0.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $18.50, 26% above the current price; targets range from $17.50 to $20.00; the consensus rating is “Strong buy”; expected EPS is $0.49 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is InfuSystem’s P/E ratio?
About 33.5, based on the last twelve months of diluted earnings per share (forward P/E about 30.0).
Is InfuSystem stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 42% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does InfuSystem pay a dividend?
Not currently.
Is InfuSystem a good stock to buy?
We do not give buy or sell advice. InfuSystem scores 2.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.